SCHEMBL9907347

SCHEMBL9907347

COC(=O)c1ccc2nccc(-c3c(F)cc(F)cc3Cl)c2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TGFBR1 P36897 1/20 0.46
HTT P42858 3/20 0.43
ALOX15 P16050 1/20 0.43
MEN1 O00255 3/20 0.43
MAPT P10636 3/20 0.43
KMT2A Q03164 3/20 0.43
ALDH1A1 P00352 2/20 0.43
TNF P01375 2/20 0.43
LMNA P02545 2/20 0.43
GAA P10253 2/20 0.43
HPGD P15428 2/20 0.43
MCL1 Q07820 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
NOD1 Q9Y239 2/20 0.43
NOD2 Q9HC29 1/20 0.43
CSNK2A1 P68400 2/20 0.43
HTR5A P47898 2/20 0.39
TP53 P04637 1/20 0.39
CASP3 P42574 1/20 0.38
SENP7 Q9BQF6 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9107247 0.92 HTT (0.48) TGFBR1HTTALOX15MEN1MAPT
SCHEMBL9907346 0.89 HTT (0.47) TGFBR1HTTALOX15MEN1MAPT
SCHEMBL9907340 0.87 TGFBR1 (0.50) TGFBR1HTTALOX15ALDH1A1SMN1; SMN2
SCHEMBL9907351 0.86 HTR5A (0.42) TGFBR1ALDH1A1HPGDCSNK2A1HTR5A
SCHEMBL9907381 0.86 HTT (0.49) TGFBR1HTTALOX15MAPTALDH1A1
SCHEMBL9907350 0.84 HTT (0.45) TGFBR1HTTALOX15MEN1MAPT
SCHEMBL9907469 0.84 TGFBR1 (0.48) TGFBR1HTTALOX15MEN1MAPT
SCHEMBL9907457 0.84 HTT (0.47) TGFBR1HTTALOX15MEN1MAPT
SCHEMBL9909210 0.83 HTT (0.46) TGFBR1HTTALOX15MEN1MAPT
SCHEMBL9907483 0.83 MAPK14 (0.37) TGFBR1HTTMEN1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
EP-2463276-B1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC (JP) 2014-03-12 EP disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
WO-2011016504-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E TGFBR1 3632/4885HTT 970/4885ALOX15 1101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.